Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

The Power and Potential of Natural Killer Cell Therapies: A New Awakening

By Christine Filippis / December 20, 2024
In a recent article published in CGTLive, Cartherics’ Prof. Alan Trounson, Karl Trounson, Dr Walid Azar and Prof. Richard Boyd,...
Read More

Cartherics awarded US$300K G-Rex grant to accelerate clinical manufacturing of CAR-NK cell therapy

By Christine Filippis / December 18, 2024
Cartherics has received a US$300K G-Rex grant to support its ‘in house’ manufacturing program Funding will enable Cartherics to generate...
Read More

Message from the CEO

By Christine Filippis / December 16, 2024
As we reflect on 2024, it's clear that this year has been a defining chapter in Cartherics' 10-year history. We've...
Read More
1 2 3 62